- Andelyn Biosciences has launched the LVV CuratorĀ® Platform, a standardized lentiviral vector manufacturing solution designed for cell and gene therapy programs.
- The platform is intended to support scalable GMP manufacturing, reduce development timelines, and improve process consistency for early-stage lentiviral vector programs.
Andelyn Biosciences has announced the launch of its LVV CuratorĀ® Platform, a lentiviral vector manufacturing solution developed to support cell and gene therapy programs transitioning from research-stage processes to GMP manufacturing.
According to the company, the platform is based on the same modular manufacturing approach used across its CuratorĀ® viral vector platform, which has supported more than 100 adeno-associated virus programs. Andelyn stated that the new LVV CuratorĀ® Platform is designed to provide a standardized and scalable framework for lentiviral vector development and manufacturing.
The company said the platform incorporates a clinically validated HEK293 cell line with established regulatory acceptance and includes process optimization, design of experiments, and GMP-focused development methodologies. Andelyn added that the system is intended to reduce development timelines, lower manufacturing costs, and improve productivity and process reproducibility.
āBy combining a proven platform foundation with a flexible, partnership-driven business model, we are helping innovators bridge the gap from discovery to clinical manufacturing more efficiently.”
Matt Niloff, Chief Commercial Officer at Andelyn Biosciences
Andelyn stated that the LVV CuratorĀ® Platform is available to both new and existing clients and is designed to support early-phase lentiviral vector programs with a pathway toward future commercial scale-up. The company said the platform further expands its CDMO and contract manufacturing capabilities for next-generation gene therapy development.
